Ziconotide: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (5 countries listed)
Risk Assessment
Black box warning for severe psychiatric symptoms including psychosis, hallucinations, paranoia, delirium, and suicidal ideation. Contraindicated in patients with history of psychosis.
Dose-related CNS effects including confusion, cognitive impairment, memory loss, abnormal gait, and ataxia. Effects are usually reversible but may be disabling during treatment.
Requires intrathecal delivery via implanted pump or external catheter. Associated risks include meningitis, catheter complications, pump malfunction, and infection.
CK elevations in approximately 40% of patients with rare reports of rhabdomyolysis and acute renal failure. Requires monitoring.
⚠️Important Warnings
- •BLACK BOX WARNING: Severe psychiatric symptoms and neurological impairment may occur. Contraindicated in patients with history of psychosis.
- •INVASIVE DELIVERY: Requires intrathecal delivery via implanted pump system. Must be administered by physicians experienced in intrathecal therapy.
- •COGNITIVE MONITORING: Patients must be monitored for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness.
- •CK MONITORING: Serum creatine kinase should be monitored periodically due to risk of rhabdomyolysis.
- •CNS DEPRESSANTS: Concomitant use with CNS depressants may potentiate neurological adverse effects.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Prescription | FDA-approved (December 2004) as Prialt for intrathecal management of severe chronic pain. Schedule not applicable (not a controlled substance). |
| United Kingdom | Prescription | Approved by MHRA. Available as Prialt for intrathecal use. |
| Canada | Prescription | Approved by Health Canada for intrathecal use. |
| European Union | Prescription | Approved by EMA (February 2005) for severe chronic pain requiring intrathecal analgesia. |
| Australia | Prescription | Approved by TGA for intrathecal use. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
Based on 30+ community reports
View community protocolsCritical Safety Information#
Ziconotide (Prialt) carries a FDA BLACK BOX WARNING for severe psychiatric symptoms and neurological impairment. It is the most serious category of safety warning issued by the FDA. Patients with a preexisting history of psychosis must not be treated with ziconotide.
Risk Categories#
Psychiatric Adverse Events (Black Box)#
Severe psychiatric symptoms have been reported in clinical trials and post-marketing surveillance, including hallucinations (12%), paranoid reactions (3%), delirium (2%), psychosis (1%), and suicidal ideation. These events can occur at any dose and at any time during treatment. New onset of psychotic symptoms requires immediate discontinuation.
Neurological Impairment#
CNS adverse effects are the most common reason for treatment discontinuation. Dizziness (up to 47%), confusion (15-33%), cognitive impairment (7-22%), abnormal gait (14-16%), and somnolence (17%) are frequently reported. Slow titration from low starting doses significantly reduces incidence and severity. Effects are generally reversible after dose reduction or discontinuation.
Invasive Delivery System Risks#
Intrathecal delivery requires surgical implantation of a pump system or placement of an external catheter. Complications include infection (including meningitis), catheter displacement, pump malfunction, CSF leak, and post-dural puncture headache. These risks are inherent to intrathecal drug delivery, not specific to ziconotide.
Metabolic Risks#
Elevated creatine kinase (CK) occurs in approximately 40% of patients, with rare cases progressing to rhabdomyolysis and acute renal failure. Regular CK monitoring is recommended during treatment.
Legal and Regulatory Status#
| Jurisdiction | Status | Notes |
|---|---|---|
| United States | Prescription (FDA-approved) | Approved December 2004 |
| European Union | Prescription (EMA-approved) | Approved February 2005 |
| United Kingdom | Prescription (MHRA-approved) | Available as Prialt |
| Canada | Prescription (Health Canada) | Approved for intrathecal use |
| Australia | Prescription (TGA-approved) | Approved for intrathecal use |
Ziconotide is not a controlled substance. It is a prescription medication requiring specialized intrathecal delivery and monitoring by experienced pain management physicians.
Risk Assessment Context#
Ziconotide belongs to the Pain category of research peptides. Risk assessment for Ziconotide should consider both the compound-specific risks identified in clinical research and the broader regulatory environment. Researchers and healthcare providers should evaluate these risks in the context of the specific patient population and therapeutic indication.
Risk Categories#
The following risk categories have been identified for Ziconotide based on available evidence and regulatory assessments:
Psychiatric Adverse Events#
Black box warning for severe psychiatric symptoms including psychosis, hallucinations, paranoia, delirium, and suicidal ideation. Contraindicated in patients with history of psychosis.
Neurological Impairment#
Dose-related CNS effects including confusion, cognitive impairment, memory loss, abnormal gait, and ataxia. Effects are usually reversible but may be disabling during treatment.
Invasive Delivery System#
Requires intrathecal delivery via implanted pump or external catheter. Associated risks include meningitis, catheter complications, pump malfunction, and infection.
Elevated Creatine Kinase#
CK elevations in approximately 40% of patients with rare reports of rhabdomyolysis and acute renal failure. Requires monitoring.
Regulatory Status by Jurisdiction#
The regulatory and legal status of Ziconotide varies by country and jurisdiction. Researchers should verify current regulations before acquiring or using this compound.
| Country | Status | Notes |
|---|---|---|
| United States | prescription | FDA-approved (December 2004) as Prialt for intrathecal management of severe chronic pain. Schedule not applicable (not a controlled substance). |
| United Kingdom | prescription | Approved by MHRA. Available as Prialt for intrathecal use. |
| Canada | prescription | Approved by Health Canada for intrathecal use. |
| European Union | prescription | Approved by EMA (February 2005) for severe chronic pain requiring intrathecal analgesia. |
| Australia | prescription | Approved by TGA for intrathecal use. |
Regulatory classifications can change. Researchers are responsible for complying with all applicable laws and regulations in their jurisdiction.
Important Warnings#
The following warnings apply to Ziconotide:
- BLACK BOX WARNING: Severe psychiatric symptoms and neurological impairment may occur. Contraindicated in patients with history of psychosis.
- INVASIVE DELIVERY: Requires intrathecal delivery via implanted pump system. Must be administered by physicians experienced in intrathecal therapy.
- COGNITIVE MONITORING: Patients must be monitored for evidence of cognitive impairment, hallucinations, or changes in mood or consciousness.
- CK MONITORING: Serum creatine kinase should be monitored periodically due to risk of rhabdomyolysis.
- CNS DEPRESSANTS: Concomitant use with CNS depressants may potentiate neurological adverse effects.
These warnings are based on available preclinical and clinical data. The absence of a warning does not indicate safety. Consult qualified professionals before making any decisions regarding peptide research.
Related Reading#
Frequently Asked Questions About Ziconotide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.